General and administrative expenses primarily consist of salaries and benefits (including employee benefit expenses and share-based compensation expenses) for administrative personnel, as well as other expenses primarily relating to professional services and our facilities and other administrative expenses. Selling and Marketing Expenses.
General and Administrative Expenses. General and administrative expenses primarily consist of salaries and benefits (including employee benefit expenses and share-based compensation expenses) for administrative personnel, as well as other expenses primarily relating to professional services and our facilities and other administrative expenses. Selling and Marketing Expenses.
Under PRC law, each of our subsidiaries and the VIEs in China is required to set aside at least 10% of its after-tax profits each year, if any, to fund certain statutory reserve funds until such reserve funds reach 50% of its registered capital.
Under PRC law, each of our PRC subsidiaries and the VIEs in China is required to set aside at least 10% of its after-tax profits each year, if any, to fund certain statutory reserve funds until such reserve funds reach 50% of its registered capital.
Our future success is significantly dependent on our ability to continually launch products and services that are popular among consumers, particularly relative to those offered by our competitors. The popularity of our products and services in turn affects users’ engagement on our platform, the data of which form a critical foundation of our research and development efforts.
Our future success is significantly dependent on our ability to continually launch new products and services that are popular among consumers, particularly relative to those offered by our competitors. The popularity of our products and services in turn affects users’ engagement on our platform, the data of which form a critical foundation of our research and development efforts.
In 2023, we recorded RMB29.1 million (US$4.1 million) in valuation allowance for deferred tax asset which is a non-cash in nature and does not materially affect our operation.
In 2023, we recorded US$4.1 million in valuation allowance for deferred tax asset which is a non-cash in nature and does not materially affect our operation.
Trend Information Other than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events since January 1, 2024 that are reasonably likely to have a material adverse effect on our net revenues, income, profitability, liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial conditions.
Trend Information Other than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events since January 1, 2025 that are reasonably likely to have a material adverse effect on our net revenues, income, profitability, liquidity or capital resources, or that caused the disclosed financial information to be not necessarily indicative of future operating results or financial conditions.
Other Income Other income primarily consists of subsidies received from local government authorities to encourage technology innovation and investment. 95 Table of Contents Results of Operations The following table sets forth a summary of our consolidated results of operations for the periods indicated, both in absolute amounts and as percentages of our total revenues.
Other Income Other income primarily consists of subsidies received from local government authorities to encourage technology innovation and investment. 88 Table of Contents Results of Operations The following table sets forth a summary of our consolidated results of operations for the periods indicated, both in absolute amounts and as percentages of our total revenues.
PRC Generally, our PRC subsidiaries, VIEs and their subsidiaries are subject to enterprise income tax on their taxable income in China at a statutory rate of 25%. A “high and new technology enterprise” is entitled to a favorable statutory tax rate of 15% and such qualification is reassessed by governmental authorities every three years.
Mainland China Generally, our PRC subsidiaries, the VIEs and their subsidiaries are subject to enterprise income tax on their taxable income in China at a statutory rate of 25%. A “high and new technology enterprise” is entitled to a favorable statutory tax rate of 15% and such qualification is reassessed by governmental authorities every three years.
Cost is determined using the weighted average method. We assess the valuation of inventory and periodically write down and write off the value for estimated excess and obsolete inventory based upon the product life cycle. 105 Table of Contents Inventories are written down if the estimated net realizable value is less than the recorded value.
Cost is determined using the weighted average method. We assess the valuation of inventory and periodically write down and write off the value for estimated excess and obsolete inventory based upon the product life cycle. 97 Table of Contents Inventories are written down if the estimated net realizable value is less than the recorded value.
Anhui Huami Health Technology Co., Ltd. began to qualify as a high and new technology enterprise since 2020, and successfully renewed its high and new technology enterprise certificate in November 2023. Shunyuan Kaihua began to qualify as a high and new technology enterprise since 2021.
Anhui Huami Health Technology Co., Ltd. began to qualify as a high and new technology enterprise since 2020, and successfully renewed its high and new technology enterprise certificate in November 2023. Shunyuan Kaihua began to qualify as a high and new technology enterprise since 2021, and successfully renewed its high and new technology enterprise certificate in October 2024.
Risk Factors—Risks Related to Doing Business in China—We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business.” If our holding company in the Cayman Islands or any of our subsidiaries outside of China were deemed to be a “resident enterprise” under the PRC Enterprise Income Tax Law, it would be subject to enterprise income tax on its worldwide income at a rate of 25%.
Risk Factors—Risks Related to Doing Business in Jurisdictions in which We Operate—We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have an adverse effect on our ability to conduct our business.” If our holding company in the Cayman Islands or any of our subsidiaries outside of China were deemed to be a “resident enterprise” under the PRC Enterprise Income Tax Law, it would be subject to enterprise income tax on its worldwide income at a rate of 25%.
We will monitor the regulatory developments and continue to evaluate the impact, if any, on our financial results. Netherlands Our subsidiaries, Zepp Europe Holding B.V. and Zepp Netherlands Trading B.V., are located in Netherlands and are subject to a two-tiered income tax rates for taxable income earned as determined in accordance with tax rules and regulations in Netherlands.
We will monitor the regulatory developments and continue to evaluate the impact, if any, on our financial results. 92 Table of Contents Netherlands Our subsidiaries, Zepp Europe Holding B.V. and Zepp Netherlands Trading B.V., are located in Netherlands and are subject to a two-tiered income tax rates for taxable income earned as determined in accordance with tax rules and regulations in Netherlands.
Anhui Huami began to qualify as a high and new technology enterprise since 2015 and renewed the high and new technology enterprise certificate in July 2018 and in September 2021.
Anhui Huami began to qualify as a high and new technology enterprise since 2015 and renewed the high and new technology enterprise certificate in July 2018, September 2021 and November 2024.
Material cash requirements Our material cash requirements as of December 31, 2023 and any subsequent interim period primarily include bank borrowings and operating lease obligations. Bank borrowings.
Material cash requirements Our material cash requirements as of December 31, 2024 and any subsequent interim period primarily include bank borrowings and operating lease obligations. Bank borrowings.
The difference between our net loss of RMB289.0 million and the net cash used in operating activities was primarily due to additional used in working capital, partially offset by the adjustment of non-cash items, which primarily consisted of shared-based compensation, depreciation and amortization expenses, non-cash lease expenses, and provision and write off for excess and obsolete inventories.
The difference between our net loss of US$43.3 million and the net cash used in operating activities was primarily due to additional used in working capital, partially offset by the adjustment of non-cash items, which primarily consisted of shared-based compensation, depreciation and amortization expenses, non-cash lease expenses, and provision and write off for excess and obsolete inventories.
Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Item 3. Key Information—D. Risk Factors” or in other parts of this annual report on Form 20-F. A.
Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Item 3. Key Information—D. Risk Factors” or in other parts of this annual report on Form 20-F. Historically, we presented our financial results in Renminbi.
Moreover, we do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or product development services with us.
Moreover, we do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or product development services with us. 98 Table of Contents
The difference between our net loss of RMB212.6 million (US$29.9 million) and the net cash provided by operating activities was primarily due to additional cash provided by working capital, as well as the adjustment of non-cash items, which primarily consisted of shared-based compensation, depreciation and amortization expenses, non-cash lease expenses, and provision and write off for excess and obsolete inventories.
The difference between our net loss of US$31.1 million and the net cash provided by operating activities was primarily due to additional cash provided by working capital, as well as the adjustment of non-cash items, which primarily consisted of shared-based compensation, depreciation and amortization expenses, non-cash lease expenses, and provision and write off for excess and obsolete inventories.
We have the obligation to either repair or replace the defect product for the customers if the product is still under warranty. At the time revenue is recognized, an estimate of warranty costs in relation to the products sold is recorded as a component of cost of revenues.
We offer a warranty ranging from one to three years. We have the obligation to either repair or replace the defect product for the customers if the product is still under warranty. At the time revenue is recognized, an estimate of warranty costs in relation to the products sold is recorded as a component of cost of revenues.
See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.” B.
See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in Jurisdictions in which We Operate—If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.” 93 Table of Contents B.
Investing activities Net cash provided by investing activities was RMB54.7 million (US$7.7 million) for the year ended December 31, 2023, primarily due to disposal of intangible assets of RMB22.2 million (US$3.1 million), disposal of long-term investments of RMB33.0 million (US$4.7 million), disposal of property, plant and equipment of RMB11.3 million (US$1.6 million), partially offset by purchase of property, plant and equipment of RMB11.3 million (US$1.6 million) and loans provided to related parties of RMB9.9 million (US$1.4 million).
Net cash provided by investing activities was US$7.7 million for the year ended December 31, 2023, primarily due to disposal of long-term investments of US$4.7 million, disposal of intangible assets of US$3.1 million, disposal of property, plant and equipment of US$1.6 million, partially offset by purchase of property, plant and equipment of US$1.6 million and loans provided to related parties of US$1.4 million.
Research and development expenses Research and development expenses decreased by 30.0% from RMB517.1 million for the year ended December 31, 2022 to RMB361.8 million (US$51.0 million) for the year ended December 31, 2023, primarily due to a decrease of RMB190.0 million (US$26.8 million) in expenses as we refined our research and development approaches to consistently evaluate resource efficiency to ensure maximum return on research and development activities in 2023, partially offset by a decrease of RMB32.4 million (US$4.6 million) in government subsidies that we received in 2023.
Research and development expenses Research and development expenses decreased by 33.4% from US$77.3 million for the year ended December 31, 2022 to US$51.5 million for the year ended December 31, 2023, primarily due to a decrease of US$26.8 million in expenses as we refined our research and development approaches to consistently evaluate resource efficiency to ensure maximum return on research and development activities in 2023, partially offset by a decrease of US$4.6 million in government subsidies that we received in 2023.
Operating lease. We have operating lease arrangements for administrative office spaces in various cities in the PRC and overseas, and financial lease that is immaterial. As of December 31, 2023, we had RMB28.3 million of payables within the next 12 months.
Operating lease. We have operating lease arrangements for administrative office spaces in various cities in the PRC and overseas, and financial lease that is immaterial. As of December 31, 2024, we had US$1.4 million of payables within the next 12 months.
General and administrative expenses General and administrative expenses decreased by 20.1% from RMB235.9 million for the year ended December 31, 2022 to RMB188.5 million (US$26.6 million) for the year ended December 31, 2023, primarily due to a decrease of RMB40.6 million (US$5.7 million) in salary and benefits as we implemented strict expense control measures.
General and administrative expenses General and administrative expenses decreased by 23.7% from US$35.1 million for the year ended December 31, 2022 to US$26.8 million for the year ended December 31, 2023, primarily due to a decrease of US$5.7 million in salary and benefits as we implemented strict expense control measures.
Our PRC subsidiaries have not paid dividends and will not be able to pay dividends until they generate accumulated profits and meet the requirements for statutory reserve funds. 104 Table of Contents The table below sets forth the respective revenues contribution and assets of Zepp and our wholly-owned subsidiaries and the VIEs as of the dates and for the periods indicated: Revenues (1) Total assets (1) For the Year Ended December 31, As of December 31, 2021 2022 2023 2022 2023 Zepp and its wholly-owned subsidiaries 16.5 % 38.8 % 60.2 % 46.2 % 53.1 % VIEs 83.5 % 61.2 % 39.8 % 53.8 % 46.9 % Total 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % Note: (1) The percentages exclude the inter-company transactions and balances between our subsidiaries and the VIEs.
Our PRC subsidiaries have not paid dividends and will not be able to pay dividends until they generate accumulated profits and meet the requirements for statutory reserve funds. 96 Table of Contents The table below sets forth the respective revenues contribution and assets of Zepp and our wholly-owned subsidiaries and the VIEs as of the dates and for the periods indicated: Revenues (1) Total assets (1) For the Year Ended December 31, As of December 31, 2022 2023 2024 2023 2024 Zepp and its wholly-owned subsidiaries 38.7 % 59.9 % 82.0 % 53.1 % 54.8 % VIEs 61.3 % 40.1 % 18.0 % 46.9 % 45.2 % Total 100.0 % 100.0 % 100.0 % 100.0 % 100.0 % Note: (1) The percentages exclude the inter-company transactions and balances between our subsidiaries and the VIEs.
Our capital expenditures were RMB53.1 million, RMB9.9 million and RMB11.9 million (US$1.7 million) in the years ended December 31, 2021, 2022 and 2023, respectively. We will continue to make capital expenditures to meet the expected growth of our business.
Our capital expenditures were US$1.5 million, US$1.7 million and US$1.5 million in the years ended December 31, 2022, 2023 and 2024, respectively. We will continue to make capital expenditures to meet the expected growth of our business.
Financing activities Net cash used in financing activities for the year ended December 31, 2023 was RMB295.0 million (US$41.6 million), primarily due to the repayment of bank borrowings of RMB735.0 million (US$103.5 million), partially offset by the bank borrowings received of RMB400.0 million (US$56.3 million).
Net cash used in financing activities for the year ended December 31, 2023 was US$41.7 million, primarily due to the repayment of bank borrowings of US$103.8 million, partially offset by the bank borrowings received of US$56.5 million.
Changes in working capital for the year ended December 31, 2022 primarily consisted of RMB904.9 million accounts payable payment settlement cash outflow, partially offset and optimize by RMB187.9 million better inventory management cash inflow and RMB210.8 million cash saving in prepaid expenses and other current assets due to better expense control.
Changes in working capital for the year ended December 31, 2022 primarily consisted of US$135.3 million accounts payable payment settlement cash outflow, partially offset and optimized by US$27.9 million better inventory management cash inflow and US$33.9 million cash saving in prepaid expenses and other current assets due to better expense control.
Selling and marketing expenses Selling and marketing expenses decreased by 31.7% from RMB460.3 million for the year ended December 31, 2022 to RMB314.6 million (US$44.3 million) for the year ended December 31, 2023, primarily due to (i) a decrease of RMB82.3 million (US$11.6 million) in advertisement promotion expenses related to our ongoing efforts to enhance our retail profitability and optimize our mix of sales channels, and (ii) a decrease of RMB56.7 million (US$8.0 million) in salary and benefits as we implemented strategic staff allocations across our various sales regions. 97 Table of Contents Operating income/(loss) As a result of the factors set out above, we recorded an operating loss of RMB410.2 million for the year ended December 31, 2022, and an operating loss of RMB207.1 million (US$29.2 million) for the year ended December 31, 2023.
Selling and marketing expenses Selling and marketing expenses decreased by 34.8% from US$68.3 million for the year ended December 31, 2022 to US$44.5 million for the year ended December 31, 2023, primarily due to (i) a decrease of US$11.6 million in advertisement promotion expenses related to our ongoing efforts to enhance our retail profitability and optimize our mix of sales channels, and (ii) a decrease of US$8.0 million in salary and benefits as we implemented strategic staff allocations across our various sales regions. 91 Table of Contents Operating loss As a result of the factors set out above, we recorded an operating loss of US$61.9 million for the year ended December 31, 2022, and an operating loss of US$30.5 million for the year ended December 31, 2023.
For the years ended December 31, 2021, 2022 and 2023, research and development expenses accounted for 42.5%, 42.6% and 41.8% of our total operating expenses and 8.2%, 12.5% and 14.5% of our revenues, respectively.
For the years ended December 31, 2022, 2023 and 2024, research and development expenses accounted for 42.8%, 41.9% and 39.3% of our total operating expenses and 12.6%, 14.6% and 25.3% of our revenues, respectively.
Research and Development Expenses. Research and development expenses primarily consist of salaries and benefits (including employee benefit expenses and share-based compensation expenses) for research and development personnel and other expenses associated with our research and development activities. General and Administrative Expenses.
Operating Expenses We classify our operating expenses into three categories: research and development, general and administrative, and selling and marketing. Research and Development Expenses. Research and development expenses primarily consist of salaries and benefits (including employee benefit expenses and share-based compensation expenses) for research and development personnel and other expenses associated with our research and development activities.
Other income/(expenses), net We had other income of RMB43.8 million in 2022 and other expenses of RMB3.7 million (US$0.5 million) in 2023. Income taxes benefits We recorded income taxes benefit in the amount of RMB65.9 million in 2022 and income taxes benefit in the amount of RMB15.8 million (US$2.2 million) in 2023.
Other income/(expenses), net We had other income of US$6.5 million in 2022 and other expenses of US$0.5 million in 2023. Income taxes benefits We recorded income taxes benefit in the amount of US$9.9 million in 2022 and income taxes benefit in the amount of US$2.4 million in 2023.
Net loss attributable to Zepp Health Corporation As a result of the foregoing, we recorded a net loss of RMB288.3 million for the year ended December 31, 2022, and a net loss of RMB212.1 million (US$29.9 million) for the year ended December 31, 2023.
Net loss attributable to Zepp Health Corporation As a result of the foregoing, we recorded a net loss of US$43.2 million for the year ended December 31, 2022, and a net loss of US$31.0 million for the year ended December 31, 2023.
Other than as discussed above, we did not have any significant capital and other commitments, long-term obligations or guarantees as of December 31, 2023. Holding Company Structure Zepp Health Corporation is a holding company with no material operations of its own. We conduct our operations in China primarily through our PRC subsidiaries, the VIEs and their subsidiaries in China.
Other than as discussed above, we did not have any significant capital and other commitments, long-term obligations or guarantees as of December 31, 2024. Holding Company Structure Zepp Health Corporation is a holding company with no material operations of its own.
Interest income Interest income represents interest earned on bank deposits. We had interest income of RMB12.3 million in 2022 and RMB21.9 million (US$3.1 million) in 2023. Interest expenses Interest expense represents interest charges for bank borrowings. We had interest expense of RMB57.0 million in 2022 and RMB47.7 million (US$6.7 million) in 2023.
Interest income Interest income represents interest earned on bank deposits. We had interest income of US$1.8 million in 2022 and US$3.1 million in 2023. Interest expenses Interest expense represents interest charges for bank borrowings. We had interest expense of US$8.4 million in 2022 and US$6.8 million in 2023.
As of December 31, 2023, the balance of the notes payable and others is RMB475.6 million, which includes RMB212.2 million payables for short-term bank acceptance notes and RMB263.4 million payable for the letter of credits factored in the bank. The short-term bank acceptance notes and the letter of credit are normally settled within three months and twelve months, respectively.
As of December 31, 2024, the balance of the notes payable and others is US$61.7 million, which includes US$25.1 million payables for short-term bank acceptance notes and US$36.6 million payable for the letter of credits factored in the bank. The short-term bank acceptance notes and the letter of credit are normally settled within three months and twelve months, respectively.
As of December 31, 2023, we had outstanding bank loans with terms of one to seven years for an aggregate balance of RMB864.1 million, including RMB12.0 million short-term bank loans and RMB537.1 million long-term bank loans used for our daily operations and RMB315.0 million long-term bank loans for the Jiangsu Yitong acquisition with the shares we hold in Jiangsu Yitong as collateral, compared to our outstanding bank loans for an aggregate balance of RMB1.2 billion as of December 31, 2022.
As of December 31, 2024, we had outstanding bank loans with terms of one to seven years for an aggregate balance of US$117.1 million, including US$39.2 million short-term bank loans and US$35.5 million long-term bank loans used for our daily operations, and US$2.7 million short-term bank loans and US$39.7 million long-term bank loans for the Jiangsu Yitong acquisition with the shares we hold in Jiangsu Yitong as collateral, compared to our outstanding bank loans for an aggregate balance of US$121.7 million as of December 31, 2023.
Changes in working capital for the year ended December 31, 2023 primarily consisted of RMB367.6 million (US$51.8 million) of cash inflow from improved inventory management and a decrease of RMB250.9 million (US$35.3 million) in accounts receivable, partially offset by a decrease of RMB191.9 million (US$ 27.0 million) in accounts payable, which was due to our effective management in raw material and component procurement and manufacturing. 102 Table of Contents Net cash used in operating activities for the year ended December 31, 2022 was RMB787.6 million.
Changes in working capital for the year ended December 31, 2023 primarily consisted of US$51.9 million of cash inflow from improved inventory management and a decrease of US$36.4 million in accounts receivable, partially offset by a decrease of US$27.8 million in accounts payable, which was due to our effective management in raw material and component procurement and manufacturing.
We expect our self-branded products to contribute to a more portion of our revenues in the future. Cost of Revenues Our cost of revenues is comprised of the following: ● material costs; ● manufacturing and fulfillment costs of our products; ● an estimate of warranty costs; and ● related expenses that are directly attributable to the production of products.
Cost of Revenues Our cost of revenues is comprised of the following: ● material costs; ● manufacturing and fulfillment costs of our products; ● an estimate of warranty costs; and ● related expenses that are directly attributable to the production of products.
Net cash used in investing activities was RMB42.3 million for the year ended December 31, 2022, primarily due to purchase of short-term investments of RMB16.3 million, loans provided to related parties of RMB15.5 million, and purchase of long-term investments of RMB12.7 million.
Net cash used in investing activities was US$6.2 million for the year ended December 31, 2022, primarily due to purchase of short-term investments of US$2.4 million, loans provided to related parties of US$2.3 million, and purchase of long-term investments of US$1.9 million.
As a result, Zepp Health Corporation’s ability to pay dividends depends upon dividends paid by our PRC subsidiaries. If our existing PRC subsidiaries or any newly formed ones incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us.
If our existing subsidiaries or any newly formed ones incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us.
The enterprise income tax is calculated based on the entity’s global income as determined under PRC tax laws and accounting standards. 100 Table of Contents We are subject to VAT at a rate of 17% (before May 1, 2018), 16% (on and after May 1, 2018 and before April 1, 2019), and 13% (on and after April 1, 2019) on sales and/or import goods and at a rate of 6% on the services (research and development services, technology services, information technology services and/or culture and creativity services), in each case less any deductible VAT we have already paid or borne.
We are subject to VAT at a rate of 17% (before May 1, 2018), 16% (on and after May 1, 2018 and before April 1, 2019), and 13% (on and after April 1, 2019) on sales and/or import goods and at a rate of 6% on the services (research and development services, technology services, information technology services and/or culture and creativity services), in each case less any deductible VAT we have already paid or borne.
For raw materials and components procured overseas, our suppliers cover the shipping costs from place of origin to China, and we are responsible for the additional logistics costs if we consign these raw materials and components to our contract manufacturers. 94 Table of Contents We offer a warranty ranging from one to three years.
Shipping costs for raw materials and components from domestic locations are borne by our suppliers and contract manufacturers. For raw materials and components procured overseas, our suppliers cover the shipping costs from place of origin to China, and we are responsible for the additional logistics costs if we consign these raw materials and components to our contract manufacturers.
The difference between our net income of RMB137.0 million and the net cash used in operating activities was primarily due to additional used in working capital, partially offset by the adjustment of non-cash items, which primarily consisted of shared-based compensation, depreciation and amortization expenses, and provision and write off for excess and obsolete inventories.
The difference between our net loss of US$75.8 million and the net cash used in operating activities was primarily due to additional cash used in working capital, partially offset by the adjustment of non-cash items, which primarily consisted of deferred income taxes, impairment loss from long-term investments, provision for excess and obsolete inventories, and depreciation and amortization expenses.
Net cash used in operating activities for the year ended December 31, 2021 was RMB232.4 million.
Net cash used in operating activities for the year ended December 31, 2022 was US$117.1 million.
Inventories, net Inventories consist of raw materials, finished goods and work in process. Inventories are stated at the lower of cost or net realizable value on a weighted average basis.
Inventories are stated at the lower of cost or net realizable value on a weighted average basis.
The decrease was primarily attributable to our repayments of RMB735.0 million in short-term and long-term bank loans in 2023. Notes payable and others.
The decrease was primarily attributable to our repayments of US$12.6 million in short-term and long-term bank loans in 2024, partially offset by bank borrowings received of US$11.0 million. Notes payable and others.
Net cash provided by financing activities for the year ended December 31, 2022 was RMB289.2 million, primarily due to proceeds from letter of credit factoring of RMB310.3 million, bank borrowings of RMB838.9 million, partially offset by the repayment of bank borrowings of RMB727.5 million.
Financing activities Net cash provided by financing activities for the year ended December 31, 2024 was US$0.5 million, primarily due to bank borrowings received of US$11.0 million and proceeds from letter of credit factoring of US$5.1 million, partially offset by repayment of bank borrowings of US$12.6 million.
Any significant changes in those estimates would result in changes in the in allocation of revenue which could have an impact on revenue. 106 Table of Contents Recent Accounting Pronouncements For a summary of recently issued accounting pronouncements, see Note 2 to the consolidated financial statements of Zepp Health Corporation and its subsidiaries pursuant to Item 17 of Part III of this annual report.
Recent Accounting Pronouncements For a summary of recently issued accounting pronouncements, see Note 2 to the consolidated financial statements of Zepp Health Corporation and its subsidiaries pursuant to Item 17 of Part III of this annual report.
For example: ● capital contributions to our PRC subsidiaries must be approved by the Ministry of Commerce or its local counterparts; and ● our loans to our PRC subsidiaries to finance their activities cannot exceed statutory limits and must be registered with the State Administration of Foreign Exchange or its local branches. See “Item 4. Information on the Company—B.
For example: ● capital contributions to our PRC subsidiaries must be approved by the Ministry of Commerce or its local counterparts; and ● our loans to our PRC subsidiaries to finance their activities cannot exceed statutory limits and must be registered with the State Administration of Foreign Exchange or its local branches. 94 Table of Contents Operating activities Net cash used in operating activities for the year ended December 31, 2024 was US$24.4 million.
Accordingly, Anhui Huami, Anhui Huami Health Technology Co., Ltd. and Shunyuan Kaihua were subject to a tax rate of 15% during the years ended December 31, 2021, 2022 and 2023.
Accordingly, Anhui Huami, Anhui Huami Health Technology Co., Ltd. and Shunyuan Kaihua were subject to a tax rate of 15% during the years ended December 31, 2022, 2023 and 2024. The enterprise income tax is calculated based on the entity’s global income as determined under PRC tax laws and accounting standards.
We may decide to enhance our liquidity position or increase our cash reserve for future investments through additional capital and finance funding. The issuance and sale of additional equity would result in further dilution to our shareholders. The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations.
The issuance and sale of additional equity would result in further dilution to our shareholders. The incurrence of indebtedness would result in increased fixed obligations and could result in operating covenants that would restrict our operations.
However, given our efficient supply chain management and industry leading market share, we believe we have the ability to control the overall level of material and manufacturing costs as percentage of revenues. 93 Table of Contents Relationship with Xiaomi Xiaomi is our exclusive distribution channel for all Xiaomi Wearable Products.
However, given our efficient supply chain management and industry leading market share, we believe we have the ability to control the overall level of material and manufacturing costs as percentage of revenues. 87 Table of Contents Key Line Items and Specific Factors Affecting Our Results of Operations Revenues We generate substantially all of our revenues from sales of smart wearable devices.
Xiaomi Wearable Products. Costs of revenues for our Xiaomi Wearable Products segment decreased by 58.7% from RMB1,394.5 million for the year ended December 31, 2022 to RMB576.1 million (US$81.1 million) for the year ended December 31, 2023. The decrease was in line with the decrease in the sales of our Xiaomi Wearable Products.
Year Ended December 31, 2023 Compared to Year Ended December 31, 2022 Revenues Our revenues decreased by 42.5% from US$613.6 million for the year ended December 31, 2022 to US$352.9 million for the year ended December 31, 2023. The decrease was primarily resulted from a 63.7% decline in the sales of Xiaomi Wearable Products.
Net cash used in investing activities was RMB1,069.3 million for the year ended December 31, 2021, primarily due to purchase of long-term investments of RMB1,072.8 million mainly used in acquiring equity interests in Jiangsu Yitong, and purchase of property, plant and equipment of RMB46.1 million, partially offset by disposal of long-term investments of RMB20.0 million.
Investing activities Net cash used in investing activities was US$1.6 million for the year ended December 31, 2024, primarily due to purchase of long-term investments of US$7.0 million, partially offset by disposal of long-term investments of US$4.9 million.
Gross profit Our gross profit decreased by 18.1% from RMB803.1 million for the year ended December 31, 2022 to RMB657.8 million (US$92.6 million) for the year ended December 31, 2023.
Cost of revenues Our cost of revenues decreased by 47.4% from US$494.8 million for the year ended December 31, 2022 to US$260.5 million for the year ended December 31, 2023. Gross profit Our gross profit decreased by 22.3% from US$118.9 million for the year ended December 31, 2022 to US$92.4 million for the year ended December 31, 2023.
(2) Includes RMB2,760.0 million, RMB1,399.5 million and RMB576.1 million (US$81.1 million) resulting from related parties sales for the years ended December 31, 2021, 2022 and 2023, respectively. (3) Share-based compensation expenses were included in operating expenses.
(2) Includes US$208.0 million, US$82.2 million and US$9.4 million resulting from related parties sales for the years ended December 31, 2022, 2023 and 2024, respectively. (3) Share-based compensation expenses were included in operating expenses. Our share-based compensation expenses were the result of our grants of options, restricted shares and restricted share units under our share incentive plans to our employees.
Net cash provided by financing activities for the year ended December 31, 2021 was RMB551.1 million, primarily due to bank borrowings of RMB1,473.6 million, including an RMB540.0 million loan with a term of seven years used in acquiring equity interests in Jiangsu Yitong, partially offset by the repayment of bank borrowings of RMB953.4 million. 103 Table of Contents Capital expenditures Our capital expenditures primarily consist of purchases of property, plant and equipment and intangible assets.
Net cash provided by financing activities for the year ended December 31, 2022 was US$42.4 million, primarily due to proceeds from letter of credit factoring of US$46.1 million, bank borrowings received of US$124.7 million, partially offset by the repayment of bank borrowings of US$108.1 million. 95 Table of Contents Capital expenditures Our capital expenditures primarily consist of purchases of property, plant and equipment and intangible assets.
Liquidity and Capital Resources The following table sets forth the movements of our cash flows for the periods presented: Years Ended December 31, 2021 2022 2023 RMB RMB RMB US$ (in thousands) Selected Consolidated Cash Flow Data: Net cash (used in)/provided by operating activities (232,435) (787,643) 298,674 42,067 Net cash (used in)/provided by investing activities (1,069,289) (42,258) 54,718 7,706 Net cash provided by/(used in) financing activities 551,077 289,198 (295,038) (41,555) Net (decrease)/increase in cash and cash equivalents and restricted cash (750,647) (540,703) 58,354 8,218 Exchange rate effect on cash and cash equivalents (15,564) 4,504 (34,376) (4,841) Cash, cash equivalents and restricted cash at the beginning of year 2,275,750 1,509,539 973,340 137,092 Cash, cash equivalents and restricted cash at end of year 1,509,539 973,340 997,318 140,469 As of December 31, 2021, 2022 and 2023, our cash, cash equivalents and restricted cash were RMB1,509.5 million, RMB973.3 million and RMB997.3 million (US$140.5 million), respectively, out of which RMB435.2 million, RMB263.4 million and RMB412.1 million (US$58.0 million) were held in U.S. dollars, and RMB1,030.7 million, RMB651.8 million and RMB546.0 million (US$76.9 million) were held in Renminbi, as of December 31, 2021, 2022 and 2023, respectively.
Liquidity and Capital Resources The following table sets forth the movements of our cash flows for the periods presented: Years Ended December 31, 2022 2023 2024 US$ US$ US$ (in thousands) Selected Consolidated Cash Flow Data: Net cash (used in)/provided by operating activities (117,114) 42,602 (24,392) Net cash (used in)/provided by investing activities (6,237) 7,727 (1,579) Net cash provided by/(used in) financing activities 42,366 (41,676) 477 Net (decrease)/increase in cash and cash equivalents and restricted cash (80,985) 8,653 (25,494) Exchange rate effect on cash and cash equivalents (14,774) (9,305) (4,240) Cash, cash equivalents and restricted cash at the beginning of year 236,880 141,121 140,469 Cash, cash equivalents and restricted cash at end of year 141,121 140,469 110,735 As of December 31, 2022, 2023 and 2024, our cash, cash equivalents and restricted cash were US$141.1 million, US$140.5 million and US$110.7 million, respectively, out of which US$38.2 million, US$58.0 million and US$63.0 million were held in U.S. dollars, and US$94.5 million, US$76.9 million and US$39.3 million were held in Renminbi, as of December 31, 2022, 2023 and 2024, respectively.
Cost of revenues for our self-branded products and others segment decreased by 35.2% from RMB1,945.3 million for the year ended December 31, 2022 to RMB1,261.4 million (US$177.7 million) for the year ended December 31, 2023. The decrease was largely in line with the decrease in shipment volume of our self-branded products, and partially attributable to our effective gross profit strategy.
The decrease was primarily in line with the decrease in the sales of our products. Gross profit Our gross profit decreased by 24.0% from US$92.4 million for the year ended December 31, 2023 to US$70.2 million for the year ended December 31, 2024.
General and administrative expenses General and administrative expenses decreased by 8.7% from RMB258.3 million for the year ended December 31, 2021 to RMB235.9 million for the year ended December 31, 2022, primarily due to a decrease of RMB23.4 million in external service fees as we implemented strict expense control measures in 2022.
We are committed to investing in new technologies and AI to maintain our competitive edge against our peers. General and administrative expenses General and administrative expenses decreased by 7.2% from US$26.8 million for the year ended December 31, 2023 to US$24.9 million for the year ended December 31, 2024, primarily due to strict administrative expense control.
Our Xiaomi Wearable Products segment revenues decreased by 62.0% from RMB1,697.1 million for the year ended December 31, 2022 to RMB644.9 million (US$90.8 million) for the year ended December 31, 2023. The decrease was primarily attributable to a decrease in shipment volume of our Xiaomi Wearable Products from approximately 14.0 million in 2022 to approximately 7.9 million in 2023.
Year Ended December 31, 2024 Compared to Year Ended December 31, 2023 Revenues Our revenues decreased by 48.3% from US$352.9 million for the year ended December 31, 2023 to US$182.6 million for the year ended December 31, 2024. The decrease in total revenues mainly resulted from an 88.0% decline in the sales of Xiaomi wearable products.
Our cash, cash equivalents and restricted cash primarily consist of cash at banks and on hand. 83.2% of our cash, cash equivalents and restricted cash as of December 31, 2023 were held in China, and 79.9% of our cash, cash equivalents and restricted cash were held by the VIEs. 101 Table of Contents We believe our current cash and cash equivalents and anticipated cash flow from operations will be sufficient to meet our current and anticipated needs for general corporate purposes for at least the next 12 months.
Our cash, cash equivalents and restricted cash primarily consist of cash at banks and on hand. 73.2% of our cash, cash equivalents and restricted cash as of December 31, 2024 were held in China, and 70.4% of our cash, cash equivalents and restricted cash were held by the VIEs.
Operating Results Key Factors Affecting Our Results of Operations Our research and development of innovative products and services We have dedicated and will continue to dedicate significant research and development efforts in developing innovative products and services, especially our self-branded products and new services as part of our healthcare initiatives.
We have a diversified product portfolio that caters to the various demands of our users and addresses different scenarios. We have dedicated and will continue to dedicate significant research and development efforts in developing innovative products and services.
Increase of brand recognition and sales of our self-branded products One of our key growth strategies is to attract new users and increase sales of our self-branded products through enhancing the brand recognition for our self-branded products. We expect our self-branded products to contribute increasingly to in the future.
Operating Results Key Factors Affecting Our Results of Operations Increase of brand recognition and sales of our products Our results of operations depend significantly on our ability to increase sales of our products. One of our key growth strategies to increase sales of our products is to enhance the brand recognition for our products.
Operating activities Net cash provided by operating activities for the year ended December 31, 2023 was RMB298.7 million (US$42.1 million).
We continued to manage working capital and inventory efficiently and recorded inventory of US$56.8 million as of December 31, 2024, the lowest level since 2018. We will continue to manage working capital tightly. Net cash provided by operating activities for the year ended December 31, 2023 was US$42.6 million.
In 2022, we recorded RMB35.2 million in valuation allowance for deferred tax asset which is a non-cash in nature and does not materially affect our operation. 99 Table of Contents Net income/(loss) attributable to Zepp Health Corporation As a result of the foregoing, we recorded a net income of RMB137.8 million for the year ended December 31, 2021, and a net loss of RMB288.3 million for the year ended December 31, 2022.
Net loss attributable to Zepp Health Corporation As a result of the foregoing, we recorded a net loss of US$31.0 million for the year ended December 31, 2023, and a net loss of US$75.7 million for the year ended December 31, 2024.
Operating income/(loss) As a result of the factors set out above, we recorded an operating income of RMB93.9 million for the year ended December 31, 2021, and an operating loss of RMB410.2 million for the year ended December 31, 2022. Interest income Interest income represents interest earned on bank deposits.
Operating loss As a result of the factors set out above, we recorded an operating loss of US$30.5 million for the year ended December 31, 2023, and an operating loss of US$47.3 million for the year ended December 31, 2024. The loss was mainly due to lower sales volume, which resulted in an inability to fully cover operating expenses.
The operating results in any period are not necessarily indicative of the results that may be expected for any future period. Years Ended December 31, 2021 2022 2023 RMB % RMB % RMB US$ % (in thousands, except for percentages) Summary of Consolidated Statements of Operating Data: Revenues (1) 6,250,109 100.0 4,142,862 100.0 2,495,322 351,459 100.0 Cost of revenues (2) 4,944,467 79.1 3,339,746 80.6 1,837,543 258,813 73.6 Gross profit 1,305,642 20.9 803,116 19.4 657,779 92,646 26.4 Operating expenses: Research and development (3) 515,081 8.2 517,122 12.5 361,812 50,960 14.5 General and administrative (3) 258,346 4.1 235,932 5.7 188,508 26,551 7.6 Selling and marketing (3) 438,273 7.1 460,304 11.1 314,563 44,305 12.6 Total operating expenses 1,211,700 19.4 1,213,358 29.3 864,883 121,816 34.7 Operating income/(loss) 93,942 1.5 (410,242) (9.9) (207,104) (29,170) (8.3) Realized gain from investments 13,507 0.2 597 — 777 109 — Interest income 16,686 0.3 12,334 0.3 21,917 3,087 0.9 Interest expenses (44,884) (0.7) (57,001) (1.4) (47,704) (6,719) (1.9) Gain from fair value change of long-term investments — — 51,817 1.3 1,249 176 0.1 Impairment loss from long-term investments — — (13,858) (0.3) (2,263) (319) (0.1) Other income/(expenses), net 27,418 0.4 43,820 1.0 (3,658) (515) (0.1) Income/(Loss) before income tax and income/(loss) from equity method investments 106,669 1.7 (372,533) (9.0) (236,786) (33,351) (9.4) Income taxes (provision)/benefit (10,745) (0.2) 65,875 1.6 15,822 2,228 0.6 Income/(Loss) before income/(loss) from equity method investments 95,924 1.5 (306,658) (7.4) (220,964) (31,123) (8.8) Income/ (loss) from equity method investments 41,028 0.7 17,657 0.4 8,382 1,181 0.3 Net income/(loss) 136,952 2.2 (289,001) (7.0) (212,582) (29,942) (8.5) Notes: (1) Includes RMB3,350.0 million, RMB1,704.0 million and RMB644.9 million (US$90.8 million) with related parties for the years ended December 31, 2021, 2022 and 2023, respectively.
The operating results in any period are not necessarily indicative of the results that may be expected for any future period. Years Ended December 31, 2022 2023 2024 US$ % US$ % US$ % (in thousands, except for percentages) Summary of Consolidated Statements of Operating Data: Revenues (1) 613,641 100.0 352,860 100.0 182,603 100.0 Cost of revenues (2) 494,784 80.6 260,502 73.8 112,369 61.5 Gross profit 118,857 19.4 92,358 26.2 70,234 38.5 Operating expenses: Research and development (3) 77,296 12.6 51,503 14.6 46,159 25.3 General and administrative (3) 35,109 5.7 26,778 7.6 24,854 13.6 Selling and marketing (3) 68,309 11.1 44,527 12.6 46,471 25.4 Total operating expenses 180,714 29.4 122,808 34.8 117,484 64.3 Operating loss (61,857) (10.1) (30,450) (8.6) (47,250) (25.9) Realized gain from investments 84 0.01 109 0.03 — — Interest income 1,818 0.3 3,089 0.9 3,672 2.0 Interest expenses (8,444) (1.4) (6,752) (1.9) (5,552) (3.0) Gain from fair value change of long-term investments 8,051 1.3 213 0.1 2,011 1.1 Impairment loss from long-term investments (2,000) (0.3) (313) (0.1) (10,129) (5.5) Other income/(expenses), net 6,454 1.1 (525) (0.1) (656) (0.4) Loss before income tax and income/(loss) from equity method investments (55,894) (9.1) (34,629) (9.8) (57,904) (31.7) Income taxes benefit/(provision) 9,865 1.6 2,430 0.7 (13,693) (7.5) Loss before income/(loss) from equity method investments (46,029) (7.5) (32,199) (9.1) (71,597) (39.2) Income/(loss) from equity method investments 2,683 0.4 1,113 0.3 (4,211) (2.3) Net loss (43,346) (7.1) (31,086) (8.8) (75,808) (41.5) Notes: (1) Includes US$253.8 million, US$92.0 million and US$11.0 million with related parties for the years ended December 31, 2022, 2023 and 2024, respectively.
We had interest income of RMB16.7 million in 2021 and RMB12.3 million in 2022. Interest expenses Interest expense represents interest charges for bank borrowings. We had interest expense of RMB44.9 million in 2021 and RMB57.0 million in 2022. Other income, net We had other income of RMB27.4 million in 2021 and other income of RMB43.8 million in 2022.
Interest income Interest income represents interest earned on bank deposits. We had interest income of US$3.1 million for the year ended December 31, 2023 and US$3.7 million for the year ended December 31, 2024. Interest expenses Interest expense represents interest charges for bank borrowings.
Year Ended December 31, 2023 Compared to Year Ended December 31, 2022 Revenues Our revenues decreased by 39.8% from RMB4,142.9 million for the year ended December 31, 2022 to RMB2,495.3 million (US$351.5 million) for the year ended December 31, 2023.
Selling and marketing expenses Selling and marketing expenses increased by 4.4% from US$44.5 million for the year ended December 31, 2023 to US$46.5 million for the year ended December 31, 2024.